Cadilarsquo

Rediff.com » News » Cadilarsquo

News for Cadilarsquo

News
Business

India's vaccine makers prepare to take on Omicron

As the Omicron variant of Sars-CoV-2 takes centrestage, vaccine makers in India are of the view that scaling up the existing vaccines to make them more effective is possible. IMAGE: A lady shows......

Despite nod foreign Covid vaccines likely to be delayed over indemnity clause

India is not keen to ‘bow down’ to demands related to indemnity against legal liabilities in case any vaccine recipient develops severe adverse reactions post inoculation. Even as......

India's children may get 2 Covid vaccines by December

While Bharat Biotech’s Covaxin is in trials among children already, Serum Institute of India will begin Novavax vaccine trials on children from July, whereas the Pfizer vaccine has been......

More Covid vaccine candidates get approval for clinical trials in India

Ahmedabad-based Zydus Cadila, Bharat Biotech’s intra-nasal candidate are among the candidates who got approval from the expert panel to conduct clinical trials, Sohini Das reports.......

India may get first Covid-19 vaccine by February

The government plans to immunise 30 million people in the first phase, starting February, and by July, the target is to vaccinate 250 million people, reports Sohini Das. IMAGE: Those on the......

No cess on Covid-19 vaccination; but rich may be charged

There was speculation that a one-time special Covid-19 cess would be imposed and that it would raise an estimated Rs 18,000 crore. Currently three vaccines - Bharat Biotech’s Covaxin,......

Why drug firms' Q2 revenue growth is likely to dip

Currency played an important role in Q2, with US dollar, Japanese yen and euro appreciating vis-a-vis the Indian rupee, while the Brazilian real, South African rand and Russian ruble depreciating......

2017 begins with a bang for outbound M&A deals

Indian companies have made acquisitions of $1 billion so far in January Outbound acquisitions by Indian companies have seen a surge in the first month of 2017 after a lull for the past three......

Strong US growth to boost pharm cos' fortune in FY14

Sun, Lupin and Dr Reddy’s to lead here, with domestic formulations expected to rebound after Sept quarter. After posting a strong 20-plus per cent growth in the March quarter, top Indian......

Rediff News

Cadilarsquo

News for Cadilarsquo

India's vaccine makers prepare to take on Omicron

Despite nod foreign Covid vaccines likely to be delayed over indemnity clause

India's children may get 2 Covid vaccines by December

More Covid vaccine candidates get approval for clinical trials in India

India may get first Covid-19 vaccine by February

No cess on Covid-19 vaccination; but rich may be charged

Why drug firms' Q2 revenue growth is likely to dip

2017 begins with a bang for outbound M&A deals

Strong US growth to boost pharm cos' fortune in FY14

Top Coverage News

World Test Championship 2023

Manipur's Tragedy

IPL 2023

Sri Lanka's Tour of India 2023

GUJARAT, HIMACHAL GO TO POLLS